Select Page


Sjogren’s, Autoimmune and Dry Eye Disease

Sometimes dry eyes are just dry eyes.  Other times, they are a red flag for other, more severe diseases.  There is a proven link between dry eye disease (DED) and autoimmune disease (AD). 

Therefore, knowing a person’s overall health complications that  lead to DED can lead to a better diagnosis of DED and treatment.

Which are the autoimmune diseases?

The Autoimmune diseases that give rise to dry eyes include, but not limited to Sjogren’s, RA (Rheumatoid Arthritis, Lupus, Hashimoto’s Thyroiditis, Raynaud’s, Graves’ Disease, Graft vs Host Disease, Chemotherapy-induced dry eyes, and more.

Check for Dry Eyes in Patients Who Don’t Complain of Dry Eyes

What?  Why would anyone check for a disease if the patient does not complain of symptoms?  Because asymptomatic patients who are diagnosed with lupus, thyroid dysfunction, Rheumatoid Arthritis (RA), or other autoimmune diseases often have had DED for a long time. They don’t realize that their symptoms are actually from DED.  This is because they believe the discomfort and blurry vision is a normal occurrence.

Risk Factors

However, if there is a significant risk factor associated with the patient. Therefore, taking a few minutes to examine the anterior segment provides a lot of information. Besides there is no additional cost to the patient.  Tear film quality and quantity, meibomian gland dysfunction, and ocular surface staining may lead to a follow-up visit for a complete dry eye workup.


Finally, screening patients early for DED actually help patients who don’t have symptoms to save their vision.  

Early detection for DED can keep a patient from permanent vision loss.

Performing a Thorough Case History, Physical Exam, and Ocular Exam

Twenty percent (20%) of the population are impacted by an autoimmune disease (AD). This means dry eye symptoms (DES) are on the rise.  Of those who suffer from AD, women make up 75% of the population. With the rising number, doctors must engage patients with an existing diagnosis, and  clues into an untreated DES condition.  A thorough case history, physical examination, and ocular examination are vital in catching any DES that may have been overlooked.

  • Case History – The most critical component of a patient exam, the case history allows for an organized and complete check of the “systems”.  However, it does not provide all of the answers.  This means a doctor needs to make a complete and confident determination of DES.
  • Physical Examination – Eye doctors are trained professionals who focus most of their attention on ocular diseases.  However, we can learn a loot by a total evaluation of a patient. Hands, posture, and even gait can reveal areas of concern that may have been overlooked by the patient.
  • Ocular Examination – There is a large group of patients who suffer from autoimmune diseases.  These patients often develop DED. Sjögren’s syndrome is a perfect example. However, other autoimmune diseases, such as lupus, rheumatoid arthritis, and scleroderma are not always recognized.

How to help those with autoimmune disease

Living with, diagnosing, and treating an autoimmune disease is difficult.  Seeing patients as a whole person, rather than just focusing on the ocular conditions, is vital in providing the best diagnosis and treatment options.

Autoimmune disease is difficult to diagnose and to treat. It is also difficult for patients to live with day to day. Therefore, careful consideration of the patient as a whole rather than exclusively from an ocular perspective is critical to both making the diagnosis and providing the best treatment options.

Why TheraLife makes a difference

TheraLife inc. located in northern California developed an all natural oral formula specifically to treat autoimmune dry eye diseases, especially Sjogren’s.  This formula helps reduce inflammation, flares and restore normal balanced tears for sustainable dry eye relief.  TheraLife Eye capsules succeed where eye drops fail.

Sjogren's treatment that works

Best Sjogren’s relief from TheraLife


To learn more, click here

Buy now

For more information, call 1-877-917-1989  US/Canada. International (650) 949-6080


Customer Story

Sjogren’s Dry Eyes – Relief by TheraLife Autoimmune

When I first found out that I had Sjogrens’ and severe dry eyes six (6) years ago.  My eye doctor put me on Restasis for the first year plus systane drops.  I used eye drops all day long with no relief.

Through out  the six years, my eyes were getting worse and I felt miserable at the end of each day.  My eyes were so red and uncomfortable – I just wanted to pull my eyes out. I was not a happy person,  very depressed, no social life,  all I wanted to do is close my eyes. I would pray  for a miracle every day, I went on line and searched for alternative medicine.

I can say my prayers have been answered. I have been on TheraLife Autoimmune for three (3) months and I have my life back again.  My family and co-workers also noticed the major difference in my eyes they are very happy for me.  TheraLife Autoimmune is worth every penny, TheaLife is the best thing that ever happened to me, its the answer to my prayers.

E A, Hollister, CA



Kaneko Y. [Diagnostic (Classification) Criteria and Treatment Guidelines of Collagen-vascular Diseases: Hos to Use and Cautions on Applying Them for General Physicians. Topics: VII. Sjögren Syndrome]. Nihon Naika Gakkai Zasshi. 2015 Oct;104(10):2149-56.
Brito-Zerón P, Retamozo S, Ramos-Casals M. Phenotyping Sjögren’s syndrome: towards a personalised management of the disease. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):198-209.
Argyropoulou OD, Valentini E, Ferro F, Leone MC, Cafaro G, Bartoloni E, Baldini C. One year in review 2018: Sjögren’s syndrome. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):14-26.
Baer AN, Akpek EK, Alevizos I., 18-21 April 2018, Washington, DC, USA. 14th International Symposium on Sjögren’s Syndrome. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):241-255. [PubMed]
Kroese FGM, Haacke EA, Bombardieri M. The role of salivary gland histopathology in primary Sjögren’s syndrome: promises and pitfalls. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):222-233. [
Kiadaliri AA, Mohammad AJ, Englund M. Hospitalizations due to systemic connective tissue diseases: Secular trends and regional disparities in Sweden, 1998-2016. Int J Rheum Dis. 2018 Nov;21(11):1900-1906.
Alani H, Henty JR, Thompson NL, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren’s syndrome (secondary Sjögren’s syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018 Mar;47(2):141-154.
Bunya VY, Fernandez KB, Ying GS, Massaro-Giordano M, Macchi I, Sulewski ME, Hammersmith KM, Nagra PK, Rapuano CJ, Orlin SE. Survey of Ophthalmologists Regarding Practice Patterns for Dry Eye and Sjogren Syndrome. Eye Contact Lens. 2018 Nov;44 Suppl 2:S196-S201.
Tzioufas AG, Goules AV. Limited efficacy of targeted treatments in Sjögren’s syndrome: why? Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):27-28. [PubMed]
De Vita S, Gandolfo S, Zandonella Callegher S, Zabotti A, Quartuccio L. The evaluation of disease activity in Sjögren’s syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):150-156.
Martel A, Coiffier G, Bleuzen A, Goasguen J, de Bandt M, Deligny C, Magnant J, Ferreira N, Diot E, Perdriger A, Maillot F. What is the best salivary gland ultrasonography scoring methods for the diagnosis of primary or secondary Sjögren’s syndromes? Joint Bone Spine. 2019 Mar;86(2):211-217.
Baer AN, Walitt B. Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults. Rheum Dis Clin North Am. 2018 Aug;44(3):419-436. [
Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, Abe S, Ono Y, Hirota T, Hirata S, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Sano H, Ogawa Y, Tsubota K, Ryo K, Saito I, Tanaka A, Nakamura S, Takamura E, Tanaka M, Suzuki K, Takeuchi T, Yamakawa N, Mimori T, Ohta A, Nishiyama S, Yoshihara T, Suzuki Y, Kawano M, Tomiita M, Tsuboi H. Clinical practice guideline for Sjögren’s syndrome 2017. Mod Rheumatol. 2018 May;28(3):383-408. [PubMed]
Seror R, Mariette X. Guidelines for treatment of primary Sjögren’s syndrome: a first useful stone but still much to do. Rheumatology (Oxford). 2017 Oct 01;56(10):1641-1642. [PubMed]
Price EJ, Rauz S, Tappuni AR, Sutcliffe N, Hackett KL, Barone F, Granata G, Ng WF, Fisher BA, Bombardieri M, Astorri E, Empson B, Larkin G, Crampton B, Bowman SJ., British Society for Rheumatology Standards, Guideline and Audit Working Group. The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome. Rheumatology (Oxford). 2017 Oct 01;56(10):e24-e48. [PubMed]
López-Pintor RM, Fernández Castro M, Hernández G. Oral involvement in patients with primary Sjögren’s syndrome. Multidisciplinary care by dentists and rheumatologists. Reumatol Clin. 2015 Nov-Dec;11(6):387-94. [PubMed]
Brito-Zerón P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Bombardieri S, de Vita S, Mandl T, Ng WF, Kruize AA, Tzioufas A, Vitali C, Buyon J, Izmirly P, Fox R, Ramos-Casals M., Eular Sjögren Syndrome Task Force. Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol. 2016;12(2):137-56. [PubMed]
Milin M, Cornec D, Chastaing M, Griner V, Berrouiguet S, Nowak E, Marhadour T, Saraux A, Devauchelle-Pensec V. Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren’s syndrome. Joint Bone Spine. 2016 Dec;83(6):681-685. [PubMed]
Flores-Chávez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Massó C, Rascón FJ, Pérez-Alvarez R, Zamora-Pasadas M, García-Pérez A, Lopez-Dupla M, Duarte-Millán MÁ, Ripoll M, Fonseca-Aizpuru E, Guisado-Vasco P, Pinilla B, de-la-Red G, Chamorro AJ, Morcillo C, Fanlo P, Soto-Cárdenas MJ, Retamozo S, Ramos-Casals M, Brito-Zerón P., GEAS-SS SEMI Registry. Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):121-129. [PubMed]
Al Hamad A, Lodi G, Porter S, Fedele S, Mercadante V. Interventions for dry mouth and hyposalivation in Sjögren’s syndrome: A systematic review and meta-analysis. Oral Dis. 2019 May;25(4):1027-1047. [PubMed]


Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Pin It on Pinterest